Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.64 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752470 | 1.00 | RORC (0.64) | RORCS1PR5S1PR1F10FUCA1 | |
| SCHEMBL14371541 | 1.00 | RORC (0.64) | RORCS1PR5S1PR1F10FUCA1 | |
| SCHEMBL1752417 | 1.00 | RORC (0.64) | RORCS1PR5S1PR1F10FUCA1 | |
| SCHEMBL12303485 | 1.00 | RORC (0.64) | RORCS1PR5S1PR1F10FUCA1 | |
| SCHEMBL8484105 | 1.00 | RORC (0.64) | RORCS1PR5S1PR1F10FUCA1 | |
| SCHEMBL1751711 | 1.00 | RORC (0.64) | RORCS1PR5S1PR1F10FUCA1 | |
| SCHEMBL2226168 | 0.91 | RORC (0.62) | RORCS1PR5S1PR1 | |
| SCHEMBL1976054 | 0.91 | RORC (0.62) | RORCS1PR5S1PR1 | |
| SCHEMBL2778415 | 0.91 | RORC (0.62) | RORCS1PR5S1PR1 | |
| SCHEMBL8210627 | 0.91 | RORC (0.62) | RORCS1PR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420487-A1 | NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120022271-A1 | NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8012998-B2 | Pyrrolidine aryl-ether as NK-3 receptor antagonists | Hoffmann—La Roche Inc. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| EP-2007787-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-7351711-B2 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | RORC 928/4885S1PR5 3915/4885S1PR1 3760/4885 |
| US-20120022271-A1 | NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND | PPOX, CBR3, ALDH18A1 | RORC 666/4885S1PR5 2532/4885S1PR1 3158/4885 |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 517/4885S1PR5 1603/4885S1PR1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.